Get the Stockscreener App
4.59
2.23%
0.10
Mannkind Corp stock is traded at $4.59, with a volume of 4.21M.
It is up +2.23% in the last 24 hours and up +20.16% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$4.49
Open:
$4.5
24h Volume:
4.21M
Relative Volume:
1.32
Market Cap:
$1.41B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
91.80
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
+11.68%
1M Performance:
+20.16%
6M Performance:
-12.24%
1Y Performance:
-27.49%
1-Day Range:
$4.50
$4.62
1-Week Range:
$3.76
$4.62
52-Week Range:
$3.3812
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.59 | 1.38B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
Trend analysis for MannKind Corporation this weekRisk Management & Reliable Entry Point Trade Alerts - Newser
How to integrate MannKind Corporation into portfolio analysis toolsMarket Volume Summary & Safe Swing Trade Setup Alerts - Newser
Applying sector rotation models to MannKind CorporationWeekly Investment Report & Weekly High Conviction Ideas - Newser
Published on: 2025-08-30 22:04:25 - Newser
Can trapped investors hope for a rebound in MannKind CorporationJuly 2025 Trade Ideas & Fast Moving Stock Trade Plans - Newser
What to expect from MannKind Corporation in the next 30 days2025 Technical Patterns & Risk Adjusted Swing Trade Ideas - Newser
How MannKind Corporation stock performs during market volatilityJuly 2025 Review & Real-Time Chart Breakout Alerts - Newser
Is now a turning point for MannKind Corporation2025 Short Interest & Risk Adjusted Buy and Sell Alerts - Newser
Historical volatility pattern of MannKind Corporation visualizedTrade Risk Assessment & Low Risk High Win Rate Picks - Newser
Full technical analysis of MannKind Corporation stockMarket Activity Report & Weekly Return Optimization Plans - Newser
Using fundamentals and technicals on MannKind CorporationVolume Spike & AI Driven Stock Reports - Newser
Does MannKind Corporation show high probability of reboundQuarterly Trade Report & Fast Moving Stock Watchlists - Newser
MannKind Buys scPharmaceuticals For $360 Million Bet: Can This Transform Its Future In Cardiorenal Care? - Smartkarma
Forecasting MannKind Corporation price range with options dataJuly 2025 Short Interest & Low Risk Growth Stock Ideas - Newser
Has MannKind Corporation formed a bullish divergence2025 Technical Patterns & AI Driven Price Predictions - Newser
When is the best time to exit MannKind CorporationWeekly Risk Report & Consistent Income Trade Ideas - Newser
Is MannKind Corporation stock reversal real or fakeWeekly Risk Report & Verified Entry Point Signals - Newser
How to recover losses in MannKind Corporation stock2025 Big Picture & Low Risk Entry Point Tips - Newser
Does MannKind Corporation fit your quant trading model2025 Price Action Summary & Reliable Price Breakout Alerts - Newser
Applying chart zones and confluence areas to MannKind CorporationPortfolio Update Summary & Proven Capital Preservation Methods - Newser
MannKind to acquire scPharmaceuticals stock in $303 million deal, H.C. Wainwright downgrades - Investing.com
MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza - Insider Monkey
Published on: 2025-08-28 23:17:11 - Newser
Volatility clustering patterns for MannKind CorporationAnalyst Downgrade & Free High Return Stock Watch Alerts - Newser
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):